<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Bally L</dc:creator>
  <dc:creator>Thabit H</dc:creator>
  <dc:date>2018</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">BACKGROUND
Despite its well-established health benefits, exercise imposes challenges on glucose control in individuals with type 1 diabetes due to the complex interactions between exerciseinduced effects on glucose metabolism and exogenous insulin therapy. Although clinical guidelines for exercise management in type 1 diabetes are available, implementation is challenging in daily life. The risk of exercise-induced dysglycaemia deters many people with type 1 diabetes from participating and benefitting from exercise. Rapid progress has been made in the development of closed-loop systems, also known as the artificial pancreas. The autonomous modulation of insulin delivery in a glucoseresponsive manner by closed-loop systems may be beneficial in addressing and overcoming the risk and burden of exercise-induced dysglycaemia.


METHODS
A summative overview of closed-loop application during exercise in type 1 diabetes is discussed, outlining current evidence and limitations, our perspectives in the field and future outlook.


RESULTS
Outcomes from clinical studies evaluating both single- and dual-hormone closed-loop during exercise are reported. Current approaches to enhance closed-loop performance during exercise are described.


CONCLUSION
Closed-loop system has the potential to ameliorate exercise management in type 1 diabetes. Promising results have been shown, however innovative approaches are still needed to overcome inherent limitations of closed-loop performance during exercise. Future studies in larger generalizable patient population during real-life settings are still needed, to further evaluate its clinical applicability.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/185136</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.2174/1573399813666170228121604</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28245784</dc:relation>
  <dc:source>Current diabetes reviews. - 2018</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Type 1 diabetes</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">artificial pancreas</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">closed-loop</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">exercise</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">glucagon</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">glucose control</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">hypoglycaemia</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">insulin.</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Algorithms</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Blood Glucose</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Blood Glucose Self-Monitoring</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Diabetes Mellitus, Type 1</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Exercise</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Insulin</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Insulin Infusion Systems</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Pancreas, Artificial</dc:subject>
  <dc:title xmlns:ns18="xml" ns18:lang="en">Closing the Loop on Exercise in Type 1 Diabetes.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
